NK cells for cancer immunotherapy

[1]  D. Plas,et al.  Gab3 is required for IL-2– and IL-15–induced NK cell expansion and limits trophoblast invasion during pregnancy , 2019, Science Immunology.

[2]  M. Altfeld,et al.  A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44 , 2019, Nature Immunology.

[3]  M. Caligiuri,et al.  Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion , 2019, Nature.

[4]  R. Eils,et al.  NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing , 2019, The Journal of experimental medicine.

[5]  T. Waldmann,et al.  First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. , 2019, Blood advances.

[6]  B. Blouw,et al.  Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti- Programmed Death-Ligand 1 Immunotherapy. , 2019, Cancer research.

[7]  A. Roussel,et al.  Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity , 2019, Cell.

[8]  N. Haigwood,et al.  Human natural killer cells mediate adaptive immunity to viral antigens , 2019, Science Immunology.

[9]  Joseph C. Sun,et al.  Cytomegalovirus Infection Drives Avidity Selection of Natural Killer Cells. , 2019, Immunity.

[10]  D. Campana,et al.  Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. , 2019, The Journal of clinical investigation.

[11]  D. Finlay,et al.  Immunometabolism and natural killer cell responses , 2019, Nature Reviews Immunology.

[12]  Junsang Doh,et al.  Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21 , 2019, Front. Immunol..

[13]  C. Pui,et al.  A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia , 2019, Journal of Immunotherapy for Cancer.

[14]  Jeffrey S. Miller,et al.  Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL. , 2019, Blood advances.

[15]  Jeffrey S. Miller,et al.  Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control , 2019, Journal of immunotherapy.

[16]  S. Linnarsson,et al.  Remodeling of secretory lysosomes during education tunes functional potential in NK cells , 2019, Nature Communications.

[17]  C. Rooney,et al.  NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors , 2019, Cancer Immunology Research.

[18]  R. Johnson,et al.  Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells , 2019, Cell.

[19]  Laura F. Dagley,et al.  Therapeutic blockade of activin-A improves NK cell function and antitumor immunity , 2019, Science Signaling.

[20]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[21]  O. Lantz,et al.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells , 2018, Cell.

[22]  Eric Vivier,et al.  High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice , 2018, Immunity.

[23]  R. Ferris,et al.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients , 2018, Cancer Immunology Research.

[24]  R. Vance,et al.  Tumor‐Derived cGAMP Triggers a STING‐Mediated Interferon Response in Non‐tumor Cells to Activate the NK Cell Response , 2018, Immunity.

[25]  É. Vivier,et al.  Natural killer cells and other innate lymphoid cells in cancer , 2018, Nature Reviews Immunology.

[26]  M. McBurney,et al.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade , 2018, The Journal of clinical investigation.

[27]  R. Locksley,et al.  Innate Lymphoid Cells: 10 Years On , 2018, Cell.

[28]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[29]  Xiaohu Zheng,et al.  Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression. , 2018, Cell metabolism.

[30]  V. Velcheti,et al.  Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors , 2018, Clinical Cancer Research.

[31]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[32]  C. Romagnani,et al.  Natural killer cell specificity for viral infections , 2018, Nature Immunology.

[33]  J. Wagner,et al.  First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. , 2018, Blood.

[34]  Jeffrey S. Miller,et al.  Clinical‐scale production of cGMP compliant CD3/CD19 cell‐depleted NK cells in the evolution of NK cell immunotherapy at a single institution , 2018, Transfusion.

[35]  S. Asthana,et al.  A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.

[36]  I. Ostrovnaya,et al.  Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study , 2018, Oncoimmunology.

[37]  J. Orange,et al.  Single Degranulations in NK Cells Can Mediate Target Cell Killing , 2018, The Journal of Immunology.

[38]  J. Walter,et al.  Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells , 2018, Nature Immunology.

[39]  Charles H. Yoon,et al.  Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.

[40]  Craig B. Davis,et al.  Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer , 2018, Clinical Cancer Research.

[41]  P. Parham,et al.  Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. , 2018, Blood.

[42]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[43]  H. Ljunggren,et al.  Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML , 2018, Clinical Cancer Research.

[44]  E. Gratton,et al.  Educated natural killer cells show dynamic movement of the activating receptor NKp46 and confinement of the inhibitory receptor Ly49A , 2018, Science Signaling.

[45]  J. Tolar,et al.  Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. , 2018, JCI insight.

[46]  J. Orange,et al.  Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.

[47]  I. Melero,et al.  Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.

[48]  D. Fremont,et al.  Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor , 2017, Cell.

[49]  Jeffrey S. Miller,et al.  Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  Deborah S. Barkauskas,et al.  A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. , 2018, Cancer research.

[51]  Jeffrey S. Miller,et al.  Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells , 2018, Cancer Immunology, Immunotherapy.

[52]  B. Becher,et al.  Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade. , 2017, Cancer research.

[53]  D. Raulet,et al.  Endothelial cells express NKG2D ligands and desensitize antitumor NK responses , 2017, eLife.

[54]  Manish R. Patel,et al.  A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[55]  M. Caligiuri,et al.  The Broad Spectrum of Human Natural Killer Cell Diversity. , 2017, Immunity.

[56]  K. Rezvani,et al.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.

[57]  Paul C. Rogers,et al.  GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. , 2017, Cancer research.

[58]  A. Schambach,et al.  Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells. , 2017, Human gene therapy.

[59]  Sara M. Federico,et al.  A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma , 2017, Clinical Cancer Research.

[60]  G. Kvalheim,et al.  A TCR-based Chimeric Antigen Receptor , 2017, Scientific Reports.

[61]  L. Galluzzi,et al.  Control of Metastasis by NK Cells. , 2017, Cancer cell.

[62]  M. Colonna,et al.  SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-β signaling , 2017, Nature Immunology.

[63]  N. Waddell,et al.  Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells , 2017, Nature Immunology.

[64]  Deborah S. Barkauskas,et al.  NK cell heparanase controls tumor invasion and immune surveillance , 2024, The Journal of clinical investigation.

[65]  G. Nolan,et al.  In silico modeling identifies CD45 as a regulator of IL-2 synergy in the NKG2D-mediated activation of immature human NK cells , 2017, Science Signaling.

[66]  H. Ljunggren,et al.  Natural killer cell-mediated immunosurveillance of human cancer. , 2017, Seminars in immunology.

[67]  Jeffrey S. Miller,et al.  Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. , 2017, Seminars in immunology.

[68]  D. Longo,et al.  Licensing delineates helper and effector NK cell subsets during viral infection. , 2017, JCI insight.

[69]  W. Wels,et al.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity , 2017, Front. Immunol..

[70]  D. Clegg,et al.  HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells , 2017, Nature Biotechnology.

[71]  Y. Kerdiles,et al.  Complement factor P is a ligand for the natural killer cell–activating receptor NKp46 , 2017, Science Immunology.

[72]  J. Ravetch,et al.  Signaling by Antibodies: Recent Progress. , 2017, Annual review of immunology.

[73]  N. Young,et al.  Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs. , 2017, Blood.

[74]  S. Holland,et al.  Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells. , 2017, Blood.

[75]  I. Melero,et al.  Targeting NK-cell checkpoints for cancer immunotherapy. , 2017, Current opinion in immunology.

[76]  J. Jansen,et al.  Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients , 2017, Clinical Cancer Research.

[77]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[78]  D. Campana,et al.  Expanded and armed natural killer cells for cancer treatment. , 2016, Cytotherapy.

[79]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[80]  R. Levy,et al.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody , 2016, Clinical Cancer Research.

[81]  F. Claas,et al.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.

[82]  R. Kiessling,et al.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. , 2016, Blood.

[83]  P. Parham,et al.  Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[84]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[85]  A. Cerwenka,et al.  Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma , 2016, Oncoimmunology.

[86]  J. Kochenderfer,et al.  Toxicities of chimeric antigen receptor T cells: recognition and management. , 2016, Blood.

[87]  Laura F. Dagley,et al.  CIS is a potent checkpoint in NK cell–mediated tumor immunity , 2016, Nature Immunology.

[88]  D. Campana,et al.  Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma , 2016, Cancer Immunology Research.

[89]  A. Copik,et al.  Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment. , 2016, Cytotherapy.

[90]  A. Tosti,et al.  Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells , 2016, Haematologica.

[91]  M. Perales,et al.  Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[92]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[93]  J. Tolar,et al.  IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function , 2016, Clinical Cancer Research.

[94]  H. Putter,et al.  Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential , 2016, Journal of immunotherapy.

[95]  J. Wagner,et al.  CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT , 2015, Leukemia.

[96]  B. Seliger,et al.  Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis , 2015, Oncoimmunology.

[97]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[98]  M. Colonna,et al.  DNAM-1 controls NK cell activation via an ITT-like motif , 2015, The Journal of experimental medicine.

[99]  Joseph C. Sun,et al.  Natural Killer Cell Memory. , 2015, Immunity.

[100]  S. Soneji,et al.  Identification of a Human Natural Killer Cell Lineage-Restricted Progenitor in Fetal and Adult Tissues. , 2015, Immunity.

[101]  M. Caligiuri,et al.  CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.

[102]  M. Altfeld,et al.  Antigen-specific NK cell memory in rhesus macaques , 2015, Nature Immunology.

[103]  Alan Maréchal,et al.  A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  S. Grace,et al.  Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial , 2015, PloS one.

[105]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[106]  L. Zitvogel,et al.  Natural killer cell mediated immunosurveillance of pediatric neuroblastoma , 2015, Oncoimmunology.

[107]  Benjamin G. Gowen,et al.  A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection , 2015, Science.

[108]  A. Copik,et al.  Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[109]  M. Smyth,et al.  Balancing natural killer cell activation through paired receptors , 2015, Nature Reviews Immunology.

[110]  S. Pittaluga,et al.  Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. , 2015, Blood.

[111]  D. Campana,et al.  Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients , 2015, Journal of immunotherapy.

[112]  W. Leung,et al.  Enhanced Cytotoxic Function of Natural Killer and CD3þCD56þ Cells in Cord Blood after Culture , 2014 .

[113]  T. Waldmann,et al.  Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  B. Payrastre,et al.  SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells , 2014, Nature Communications.

[115]  L. Avanesyan,et al.  Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients , 2014, Proceedings of the National Academy of Sciences.

[116]  D. Campana,et al.  Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15. , 2014, Blood.

[117]  J. Wagner,et al.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[118]  Bin Zhang,et al.  Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. , 2014, Blood.

[119]  Jeffrey S. Miller,et al.  Clinical utility of natural killer cells in cancer therapy and transplantation. , 2014, Seminars in immunology.

[120]  T. Fehniger,et al.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[121]  M. Speicher,et al.  Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients , 2014, Science Translational Medicine.

[122]  D. Campana,et al.  4-1BB Chimeric Antigen Receptors , 2014, Cancer journal.

[123]  J. Orange,et al.  GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. , 2014, Blood.

[124]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[125]  J. Orange,et al.  HEMATOPOIESIS AND STEM CELLS GATA 2 de fi ciency : a protean disorder of hematopoiesis , lymphatics , and immunity , 2014 .

[126]  Dario Campana,et al.  T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. , 2014, Cancer research.

[127]  M. Caligiuri,et al.  Location and cellular stages of natural killer cell development. , 2013, Trends in immunology.

[128]  Y. Natkunam,et al.  Expression of the activating receptor, NKp46 (CD335), in human natural killer and T-cell neoplasia. , 2013, American journal of clinical pathology.

[129]  R. Badolato,et al.  Occurrence of Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Hermansky-Pudlak Type 2 Syndrome Is Associated to Natural Killer and Natural Killer T Cell Defects , 2013, PloS one.

[130]  O. Janssen,et al.  Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17 , 2013, International journal of cancer.

[131]  J. Orange.  Natural killer cell deficiency. , 2013, Journal of Allergy and Clinical Immunology.

[132]  Rudolf Jaenisch,et al.  Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. , 2013, Blood.

[133]  O. Janssen,et al.  Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications , 2013, Scandinavian journal of immunology.

[134]  J. Lifson,et al.  Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15·IL-15Rα Cytokine Compared to IL-15 Monomer* , 2013, The Journal of Biological Chemistry.

[135]  M. Yarmush,et al.  Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy , 2013, Front. Immunol..

[136]  J. Orange,et al.  Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling. , 2013, Blood.

[137]  D. Kaufman,et al.  Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy , 2013, Stem cells translational medicine.

[138]  S. Gasser,et al.  Regulation of ligands for the NKG2D activating receptor. , 2013, Annual review of immunology.

[139]  D. Campana,et al.  A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. , 2013, Cancer research.

[140]  D. Campana,et al.  Natural killer cell reprogramming with chimeric immune receptors. , 2013, Methods in molecular biology.

[141]  A. Cerwenka,et al.  Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors , 2012, The Journal of experimental medicine.

[142]  T. Fehniger,et al.  Cytokine activation induces human memory-like NK cells. , 2012, Blood.

[143]  M. Caligiuri,et al.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. , 2012, Blood.

[144]  J. Bourhis,et al.  A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. , 2012, Blood.

[145]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[146]  D. Campana,et al.  A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. , 2012, Cytotherapy.

[147]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[148]  L. Hurton,et al.  Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.

[149]  M. Caligiuri,et al.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. , 2011, Blood.

[150]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[151]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[152]  S. Rosenberg,et al.  Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.

[153]  W. Yokoyama,et al.  Unifying concepts of MHC-dependent natural killer cell education. , 2011, Trends in immunology.

[154]  Harry Dolstra,et al.  Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process , 2011, PloS one.

[155]  S. H. van der Burg,et al.  HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes , 2011, Proceedings of the National Academy of Sciences.

[156]  Jan Tavernier,et al.  Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.

[157]  C. Lutz,et al.  Human NK Cells Proliferate and Die In Vivo More Rapidly than T Cells in Healthy Young and Elderly Adults , 2011, The Journal of Immunology.

[158]  Baptiste N. Jaeger,et al.  Confinement of Activating Receptors at the Plasma Membrane Controls Natural Killer Cell Tolerance , 2011, Science Signaling.

[159]  L. Downs,et al.  A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.

[160]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[161]  D. Campana,et al.  Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. , 2010, Methods in molecular biology.

[162]  Chap T Le,et al.  Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. , 2010, Blood.

[163]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  D. Raulet,et al.  Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment , 2010, The Journal of experimental medicine.

[165]  K. Anderson,et al.  Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. , 2010 .

[166]  C. Pui,et al.  NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  J. Skepper,et al.  Differential Mechanisms of Shedding of the Glycosylphosphatidylinositol (GPI)-anchored NKG2D Ligands* , 2010, The Journal of Biological Chemistry.

[168]  M. Caligiuri,et al.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. , 2009, Blood.

[169]  D. Campana,et al.  2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells , 2009, Clinical Cancer Research.

[170]  Eric O Long,et al.  Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. , 2009, Immunity.

[171]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[172]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[173]  D. Campana,et al.  Replicative potential of human natural killer cells , 2009, British journal of haematology.

[174]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[175]  Sofia Johansson,et al.  The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. , 2009, Blood.

[176]  Liping Yang,et al.  Cytokine-induced memory-like natural killer cells , 2009, Proceedings of the National Academy of Sciences.

[177]  A. Angulo,et al.  IL-12-Dependent Inducible Expression of the CD94/NKG2A Inhibitory Receptor Regulates CD94/NKG2C+ NK Cell Function1 , 2009, The Journal of Immunology.

[178]  Peter Parham,et al.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. , 2009, Blood.

[179]  B. Seliger,et al.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas , 2008, Proceedings of the National Academy of Sciences.

[180]  J. Orange.  Formation and function of the lytic NK-cell immunological synapse , 2008, Nature Reviews Immunology.

[181]  R. Strong,et al.  Structural basis for NKG2A/CD94 recognition of HLA-E , 2008, Proceedings of the National Academy of Sciences.

[182]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[183]  H. Ljunggren,et al.  Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. , 2008, Blood.

[184]  Margaret Comerford Freda,et al.  10 Years. , 2008, MCN. The American journal of maternal child nursing.

[185]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[186]  D. Tough,et al.  In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection , 2007, Immunology.

[187]  R. Vance,et al.  Self-tolerance of natural killer cells , 2006, Nature Reviews Immunology.

[188]  H. Salih,et al.  Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. , 2006, Human immunology.

[189]  藤井 俊策.  子宮 natural killer 細胞の測定意義 , 2006 .

[190]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[191]  J. Zimmer,et al.  Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. , 2005, Blood.

[192]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[193]  L. Lanier,et al.  IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism1 , 2005, The Journal of Immunology.

[194]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[195]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[196]  Eric O Long,et al.  Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). , 2005, Blood.

[197]  K. Wucherpfennig,et al.  The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[198]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[199]  T. Waldmann,et al.  Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. , 2005, Blood.

[200]  Sandro Sorella,et al.  Recent progress with the , 2005 .

[201]  A. Gratwohl,et al.  Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation , 2004, Leukemia.

[202]  H. Harada,et al.  A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. , 2004, Experimental hematology.

[203]  D. Campana,et al.  Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.

[204]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[205]  P. Kuppen,et al.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. , 2003, Trends in immunology.

[206]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[207]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[208]  D. Vesole,et al.  IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial , 2003, Bone Marrow Transplantation.

[209]  M. Farrar,et al.  In Vivo Survival and Homeostatic Proliferation of Natural Killer Cells , 2003, The Journal of experimental medicine.

[210]  H. Klingemann,et al.  Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. , 2003, Cytotherapy.

[211]  R. Kiessling,et al.  IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. , 2002, The Journal of clinical investigation.

[212]  T. Waldmann,et al.  IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells , 2002 .

[213]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[214]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[215]  G. Damonte,et al.  Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.

[216]  M. Collins,et al.  IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. , 2002, Immunity.

[217]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[218]  J. Coligan,et al.  Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. , 2002, Molecular immunology.

[219]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[220]  T. Waldmann,et al.  IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. , 2002, Immunity.

[221]  A. Nagler,et al.  Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. , 2001, Experimental hematology.

[222]  M. Caligiuri,et al.  Interleukin 15: biology and relevance to human disease. , 2001, Blood.

[223]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[224]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[225]  Scott R. Presnell,et al.  Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function , 2000, Nature.

[226]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[227]  K. Schwarz,et al.  Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children , 1999, Bone Marrow Transplantation.

[228]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[229]  Jun Wu,et al.  An activating immunoreceptor complex formed by NKG2D and DAP10. , 1999, Science.

[230]  M. Caligiuri,et al.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. , 1999, Journal of immunology.

[231]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[232]  C. Thompson,et al.  4-1BB and Ox40 Are Members of a Tumor Necrosis Factor (TNF)-Nerve Growth Factor Receptor Subfamily That Bind TNF Receptor-Associated Factors and Activate Nuclear Factor κB , 1998, Molecular and Cellular Biology.

[233]  L. Moretta,et al.  p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell Activation , 1997, The Journal of experimental medicine.

[234]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[235]  L. Lanier,et al.  Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. , 1997, Journal of immunology.

[236]  M. Carretero,et al.  The CD94 and NKG2‐A C‐type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules , 1997, European journal of immunology.

[237]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.

[238]  L. Lanier,et al.  Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. , 1996, Journal of immunology.

[239]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.

[240]  J. Ritz,et al.  Costimulatory signals are required for optimal proliferation of human natural killer cells. , 1993, Journal of immunology.

[241]  L. Lanier,et al.  The developmental relationship between NK cells and T cells. , 1992, Immunology today.

[242]  R. Testi,et al.  Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule , 1989, The Journal of experimental medicine.

[243]  S. Rosenberg,et al.  Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. , 1987, Blood.

[244]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[245]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[246]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[247]  S Marsoni,et al.  The phase II trial. , 1985, Cancer treatment reports.

[248]  L. Lanier,et al.  A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562 , 1985, The Journal of experimental medicine.

[249]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[250]  J. Roth,et al.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.

[251]  J. Bender,et al.  Phase I Trial , 1983 .

[252]  J. Ortaldo,et al.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells , 1981, The Journal of experimental medicine.

[253]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity , 1975, International journal of cancer.

[254]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[255]  C. Pochedly.  Recognition and Management , 1971 .